TPI1 Loss Triggers a Metabolite‐Driven Mitochondrial Redox Vulnerability via the SARM1–cADPR–Ca 2+ Axis
Advanced Science · 2026
DOI: 10.1002/advs.76614 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Chunyu Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Urology, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Mitochondria, Calcium, Cyclic ADP-Ribose, Cytoskeletal Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Minimally Invasive Innovation Team of the Urology Department of the Chinese PLA General Hospital, Pioneer Program for Discipline Innovation and Development of the Third Medical Center of PLA General Hospital, the Priority Specialty in Medicine.
Abstract (Originalsprache)
Cellular senescence is a stable cell cycle arrest program with important therapeutic implications in cancer, yet how metabolic perturbations are translated into redox‐dependent senescence remains incompletely understood. Here, we identify triosephosphate isomerase 1 (TPI1) as a critical regulator of senescence in clear cell renal cell carcinoma (ccRCC) through a customized CRISPR‐Cas9 metabolic screen. TPI1 depletion induces a robust senescence phenotype characterized by mitochondrial redox imbalance, DNA damage, and stable growth arrest. Mechanistically, loss of TPI1 leads to accumulation of dihydroxyacetone phosphate (DHAP), which engages a SARM1‐dependent signaling pathway, resulting in increased cyclic ADP‐ribose (cADPR) production and intracellular Ca 2+ release. This cADPR‐Ca 2+ axis drives mitochondrial ROS (mtROS) generation, thereby promoting DNA damage and activation of the p53‐p21 pathway to enforce senescence. Pharmacological or genetic attenuation of calcium signaling, or mitochondrial ROS partially rescues these phenotypes, indicating that calcium‐dependent redox stress is required for senescence induction. Importantly, this metabolic–redox signaling cascade is conserved across multiple cancer types. Collectively, our findings define a previously unrecognized TPI1–SARM1–cADPR–Ca 2+ axis that links glycolytic metabolite accumulation to mitochondrial redox stress and cellular senescence, highlighting a metabolite‐driven redox vulnerability that may be therapeutically exploitable in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior Department of Urology, Chinese PLA General Hospital, Beijing, China.
- Medical Schhool of PLA, Beijing, China.
- Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China.
ORCID-Profile: Xu Zhang
Förderung
- Minimally Invasive Innovation Team of the Urology Department of the Chinese PLA General Hospital
- Pioneer Program for Discipline Innovation and Development of the Third Medical Center of PLA General Hospital
- the Priority Specialty in Medicine
- The "3+1" Innovative Talent Program of the Chinese PLA General Hospital
Zitieren
APA
Liu, C., Wu, S., Wang, C., Zhou, Z., Cai, T., Tao, W., Zuo, S., Zhang, C., Dong, Y., Feng, Y., Huang, Q., Wang, B., Ma, X., Ma, H., Zhang, X., & Huang, Y. (2026). TPI1 Loss Triggers a Metabolite‐Driven Mitochondrial Redox Vulnerability via the SARM1–cADPR–Ca 2+ Axis. Advanced Science. https://doi.org/10.1002/advs.76614
Vancouver
Liu C, Wu S, Wang C, Zhou Z, Cai T, Tao W, et al. TPI1 Loss Triggers a Metabolite‐Driven Mitochondrial Redox Vulnerability via the SARM1–cADPR–Ca 2+ Axis. Advanced Science. 2026. doi:10.1002/advs.76614
BibTeX
@article{Liu2026,
author = {Liu, Chunyu and Wu, Shun and Wang, Chuang and Zhou, Zirui and Cai, Tianwei and Tao, Wen and Zuo, Shidong and Zhang, Chi and Dong, Yuhao and Feng, Yi and Huang, Qingbo and Wang, Baojun and Ma, Xin and Ma, Haoli and Zhang, Xu and Huang, Yan},
title = {TPI1 Loss Triggers a Metabolite‐Driven Mitochondrial Redox Vulnerability via the SARM1–cADPR–Ca 2+ Axis},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76614}
}
EUVIMED